NAYA Therapeutics is focused on the clinical development and strategic acquisition of first & best-in-class clinical-stage therapeutics for the treatment of cancer & autoimmune diseases.

We leverage the impact of new drug modalities, novel targets, and AI-powered translational medicine to achieve breakthrough outcomes for patients.

NAYA Therapeutics has 2 development franchises, NAYA Therapeutics - Solid Tumors and NAYA Therapeutics - Immunotherapy. 

The Solid Tumors franchise is advancing two novel therapeutics for the treatment of hepatocellular carcinoma (HCC):


 












The Immunotherapy franchise is advancing a novel therapeutic for the treatment of both multiple myeloma & autoimmune diseases:








 
 
Data for NY-303 & NY-338 has been presented at major oncology meetings, including ASH, AACR, SITC, ESMO, and ASGCT.

Clinical development has been designed by our scientific advisory board of leading liver cancer, multiple myeloma, and autoimmune disease experts to allow for early inflection points and accelerated development based on early data.